Observation 2: a 45-year-old woman, with no notable pathological history, consulted in our facility for a left sub-angulo-mandibular mass evolving for approximately 4 months. There were slight inflammatory signs nearby, particularly a slight redness with pain and fever at 38 C without weight loss, chewing discomfort, trismus, or pus exit at salivary orifices. The young woman was in good general condition and had a swelling of the left parotid area, firm, painless, measuring about 4 cm in long axis, and fixed. There was no limitation of the mouth opening or peripheral facial paralysis. Examination of the oral cavity and the opening of the stenon canal did not reveal any inflammation or pus output. Examination of the cervical lymph node areas was normal. The rest of the ENT and general examination was without any particularity. A cervical ultrasound was done to show a tumor lesion, measuring 29 x 28 x 14 mm, of mixed echostructure with central liquid predominance at the lower pole of the left parotid. Parotid MRI showed a lesional process in the deep compartment of the left parotid gland, with low intensity T1 signal, and in the other hand, high intensity signal in diffusion sequence with peripheral enhancement, measuring 30 x 29 x 15 mm. The right parotid and submandibular glands, in addition to the thyroid are without signal or morphological abnormalities. This was in favor of a left parotid abscess (Figure 4). The rest of the biological test, as well as the chest x-ray, were normal. The patient was operated benefiting conservative parotidectomy of the facial nerve. Histopathological study of the cyst wall found epithelial-gigantocellular granuloma with caseous necrosis. The culture of the puncture fluid on Lowenstein-Jensen medium revealed an acid-resistant bacillus, which allowed us to confirm the diagnosis of primary tuberculosis of the parotid gland. The young woman received a medical treatment of antituberculosis drugs combining an initial phase of 2 months based on rifampicin, isoniazid, ethambutol, pyrazinamide, followed by a consolidation phase of 4 months combining Rifampicin and Isoniazid. The evolution was favourable within 9 months after the end of the treatment.